Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Total Liabilities

Everything the company owes to creditors and other parties.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Total Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total liabilities rises 98.4% from a year ago

Total liabilities stood at $31.57M at the end of Q1 FY2026, up 98.4% from a year earlier and down 5.5% from the prior quarter. Over 3 fiscal years it compounded at -9.0% a year.

Context

  • Total liabilities amounted to 31.6% of total assets at the end of Q1 FY2026, up 20.1 pp from a year earlier.
  • Total liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total liabilities keeps rising in the next quarterly balance sheet after a +98.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.57M-5.5% QoQ
Last fiscal yearDec 2025
$33.41M+88.8% YoY
Year agoMar 2025
$15.91M+98.4% since
Total Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+98.4%——
1 year+88.8%——
3-year CAGR-9.0%——
5-year CAGR——
10-year CAGR——

Total Liabilities history

USD · from the balance sheet

Latest · FY2025
33.41M USD
Year-over-year change
+88.8%
4-year CAGR
-12.6%

Total Liabilities vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +98.4% is the highest of 9, against a peer median of -8.5%.
  • Total liabilities amounts to 31.6% of total assets for AVTX, versus a peer median of 27.3%.
AVTX Competitors
Total Liabilities for AVTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANABAnaptysBio, Inc.Mar 2026$316.94M USD-18.3%-2.1%96.1%
XNCRXencor, Inc.Jun 2026$221.73M USD-14.4%+26.4%30.6%
ACRSAclaris Therapeutics, Inc.Mar 2026$55.07M USD+1.9%+0.2%27.7%
SYRESpyre Therapeutics, Inc.Sep 2026$48.19M USD-2.6%+44.2%4.4%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$46.21M USD-1.1%+117.0%31.5%
IMUXImmunic, Inc.Mar 2026$38.51M USD+49.2%+29.7%20.3%
AVTXAvalo Therapeutics, Inc.Mar 2026$31.57M USD+98.4%-9.0%31.6%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€18.7M EUR——11.3%
QTTBQ32 Bio Inc.Mar 2026$17.36M USD-79.1%-53.2%27.3%
IFRXInflaRx N.V.Mar 2026€12.01M EUR-27.4%-0.9%24.5%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —-8.5%+13.3%27.3%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents54.59M13.17M7.42M134.55M15.86M
Short-term Investments000082.48M
Net Receivables4.8M1.92M136K611K0
Inventory38K20K000
Other Current Assets51K1.31M844K3.73M6.95M
Total Current Assets61.85M16.42M8.4M138.89M105.29M
Property, Plant & Equipment (Net)2.7M2.41M1.97M1.21M460K
Goodwill14.41M14.41M10.5M10.5M10.5M
Intangible Assets38K0000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.23M131K131K131K210K
Total Non-current Assets18.37M16.95M12.6M11.84M11.17M
Total Assets80.21M33.37M20.99M150.73M116.46M
Account Payables3.37M2.88M446K283K137K
Short-term Debt05.93M000
Tax Payables00000
Deferred Revenue088K000
Other Current Liabilities4.32M3.18M3.06M3.24M12.41M
Total Current Liabilities19.89M22.11M4.62M6.96M12.94M
Long-term Debt32.83M13.49M002M
Deferred Tax Liabilities113K141K155K270K434K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities4.3M8.54M8.92M10.47M18M
Total Non-current Liabilities37.24M22.17M9.07M10.74M20.47M
Total Liabilities57.13M44.28M13.69M17.7M33.41M
Common Stock9K01K10K18K
Retained Earnings(262.17M)(303.82M)(335.13M)(370.26M)(448.52M)
Accumulated OCI000068K
Other Stockholders Equity00000
Minority Interest00000
Total Equity23.08M(10.92M)7.3M133.03M83.05M
Total Debt33.32M19.95M537K568K2.43M
Net Debt(21.27M)6.78M(6.88M)(133.98M)(13.43M)

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.